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ABSTRACT
Purpose: Diflomotecan (BN80915) is an E-ring modified
camptothecin analogue that possesses greater lactone stabil-
ity in plasma compared with other topoisomerase I inhibi-
tors, a potential advantage for antitumor activity. As with
other camptothecins, oral administration has pharmacolog-
ical and clinical advantages. This Phase I study was per-
formed to assess the feasibility of the administration of oral
diflomotecan, to determine the maximum-tolerated, dose its
bioavailability, and to explore the pharmacokinetics.
Experimental Design: An initial i.v. bolus was adminis-
tered to assess the bioavailability of diflomotecan. Fourteen
days later, diflomotecan was administered p.o. once daily for
5 days to adult patients with solid malignant tumors and
repeated every 3 weeks. BN80915 and its open lactone form
BN80942 were measured.
Results: Twenty-two patients entered the study and
received a total of 57 cycles of oral diflomotecan at flat dose
levels of 0.10, 0.20, 0.27, and 0.35 mg. The main toxicity was
hematological, but some patients experienced alopecia, mild
gastrointestinal toxicity, and fatigue. At the 0.35-mg dose
level, 2 of 4 patients experienced dose-limiting toxicity com-
prising grade 3 thrombocytopenia with epistaxis and febrile
neutropenia in 1 patient and uncomplicated grade 4 neutro-
penia lasting for >7 days in another. Toxicity was accepta-
ble at the 0.27-mg dose level at which dose-limiting toxicities
were observed in 3 of 12 patients (grade 4 neutropenia > 7
days, complicated by fever in 1 patient but without other
signs of infection). After two cycles of diflomotecan, 6 pa-
tients had disease stabilization, which was maintained in 2
patients for 9 months and >1 year, respectively.
Diflomotecan pharmacokinetics were linear over the
dose range studied. Systemic exposure correlated with the
fall in WBC counts. The mean oral bioavailability (SD)
was 72.24  59.2% across all dose levels. Urinary excretion
of BN80915 was very low.
Conclusions: The recommended oral diflomotecan dose
for Phase II studies is 0.27 mg/day  5 every 3 weeks. This
regimen is convenient and generally well tolerated with a
favorable pharmacokinetic profile and high but variable
bioavailability.
INTRODUCTION
The fluorinated homocamptothecin diflomotecan
BN809152 is a recently developed water-insoluble topoi-
somerase I inhibitor (1, 2). Homocamptothecins are campto-
thecin analogues bearing a seven-membered -hydroxylac-
tone ring, with enhanced lactone stability, instead of the
naturally occurring six-membered -hydroxylactone. Be-
cause a one-carbon ring expansion is chemically termed a
homoligation, these new lactone- or E-ring-modified com-
pounds were named homocamptothecins. Because of the en-
hanced stability of the active form, homocamptothecins were
expected to exert greater topoisomerase I inhibition and
antitumor efficacy than the currently used analogues such as
irinotecan and topotecan. This was confirmed in vivo, with
i.p. and oral administration, in murine leukemia, human colon
carcinoma, melanoma, pancreatic and ovarian cancer, brain
glioblastoma, prostate and (non-)small cell lung tumor mice
models (3– 6), and ex vivo in human colon cancers (7).
Topoisomerase I inhibitors in vitro show more pronounced
antitumor activity with protracted exposure. This can be
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achieved with oral therapy, and because this is a more conven-
ient and less expensive means of treatment (8), oral administra-
tion of diflomotecan was chosen for this study. In preclinical
studies, absolute oral bioavailability of the compound ranged
from 30% in rats (9) to 60% in dogs (10). Radioactivity studies
in rats showed that BN80915, its lactone open ring analogue
BN80942 and metabolites, were mainly recovered in the feces
(69–74%), with 16% in urine. After oral administration in
mice, toxicity consisted mainly of alopecia and gastrointestinal
side effects (11). The LD10 in these studies was 2.7 mg/m2.
We conducted a Phase I pharmacological and bioavailabil-
ity study of diflomotecan administered p.o. once daily for 5 days
every 3 weeks to adult patients with solid malignant tumors. For
other topoisomerase I inhibitors, fixed or flat dosing is as
effective as dosing/square meter (12). Given the interpatient
pharmacokinetic and pharmacodynamic variability after oral
administration, we decided to use the more convenient flat
dosing approach in this study. The aims of this Phase I study
were to assess the feasibility of oral administration of diflomo-
tecan to humans, to determine its maximum-tolerated dosage
and bioavailability, and to explore pharmacokinetics and also
pharmacodynamic correlations.
MATERIALS AND METHODS
Patient Selection. Eligible patients had histological or cy-
tological proof of a solid malignant tumor that was resistant to
standard forms of therapy or for whom no active standard therapy
was available. Other inclusion criteria included the following: age
at least 18 years; WHO performance status 2; no recent previous
chemotherapy and/or radiotherapy; adequate hematopoietic func-
tion (absolute neutrophil count  1.5  109/liter and platelet
count 100 109/liter), renal function (creatinine clearance 60
ml/min or serum creatinine 1.5 the ULN), and liver biochemistry
[total serum bilirubin level  1.25  ULN and serum AST and
ALT levels 2.5  ULN in the presence of liver metastasis AST
and ALT were allowed 5  ULN]. An additional exclusion
criterion was any condition precluding oral intake or gastrointesti-
nal absorption. The local medical ethical committees of the partic-
ipating institutions in Rotterdam and Glasgow approved the study
protocol and all patients gave written informed consent before
entering the study.
Dosage and Dose Escalation. Two weeks after a single
20-min i.v. infusion of diflomotecan, escalating doses of oral di-
flomotecan were administered daily for 5 days every 3 weeks. The
starting i.v. and oral dose was 0.1 mg/day, giving a total oral dose
of 0.5 mg/oral cycle; this is 10% of the estimated LD10 in mice.
Dose escalation depended on toxicities at the prior dose level.
Except for the initial dose level, the i.v. dose level was equal to the
next lower oral dose level to avoid toxicity from the i.v. drug
because otherwise systemic exposure from the i.v. administration
would have been higher than after oral administration at the same
dose level. At least 3 patients were treated at each dose level. If 1
of 3 patients experienced DLT, 3 additional patients were entered
at that dose level. The RD was defined as the dose level below that
which induced DLT in at least one-third of the patients (i.e.,2 of
3 or 6 patients). Additional patients were included at the RD up to
a total of 12 patients to additionally assess safety, pharmacokinet-
ics, and pharmacodynamics. DLT was defined as grade 4 neutro-
penia (NCI-CTC version 2.0) lasting 8 days, grade 3 or 4 neu-
tropenia complicated by fever, grade 4 thrombocytopenia or grade
3 complicated with hemorrhage, and/or grade 3 nonhematologi-
cal toxicity, excluding inadequately treated nausea and vomiting. If
a patient experienced DLT, the dose of diflomotecan was decreased
by one dose level at the time of re-treatment if the patient remained
on therapy. Treatment was delayed until the absolute neutrophil
count had recovered to 1.5  109/liter and platelet count to
100  109/liter and continued so long as there was no disease
progression and toxicity was acceptable unless this was considered
not in the best interest of the patient.
Drug Administration. Diflomotecan was supplied by Ip-
sen Biotech (Paris, France) in brown-glass vials containing 20 mg
of the compound, with 3.3 ml of dimethyl acetamide and a glass
bottle of solvent, containing 3.5 g of Montanox VGDF80 and 0.4 g
of sodium chloride and water for injection to make up 200 ml of
aqueous, sterile isotonic solution. For reconstituting the product,
the 3.3-ml vial of diflomotecan was diluted with the solvent,
protected from light and stored at 2–8°C. In aqueous solution, the
stability of diflomotecan at room temperature is adequate for the
expected duration of the i.v. infusion and oral administrations. The
i.v. administration consisted of a 20-min infusion. The appropriate
volume of reconstituted drug was prepared in syringes and admin-
istered p.o. by the patient daily for 5 days every 3 weeks. The
solution was taken on an empty stomach in the morning. The
complete dose was directly swallowed, followed immediately by
up to 150 ml of water. If the patient complained about the taste of
the diflomotecan, he/she was allowed to drink Coca-Cola instead of
water (after a protocol amendment, initiated after the second dose
level), diflomotecan being stable in this beverage in drug stability
studies. Routine premedication was not prescribed. In case of
nausea or vomiting, prophylactic metoclopramide or domperidone
was prescribed for subsequent cycles.
Treatment Assessment. Before therapy a complete med-
ical history was taken and physical examination performed. A
complete blood cell count, including WBC differential and serum
biochemistry, comprising sodium, potassium, calcium, chloride,
urea, creatinine, total protein, albumin, total bilirubin, alkaline
phosphatase, AST, ALT, -glutamyl transferase, lactate dehydro-
genase, and glucose, were performed, as was measurement (24-h
urine collection) of creatinine clearance and urine analysis. Weekly
evaluations included history, physical examination, toxicity assess-
ment according to the NCI-CTC version 2.0, and serum chemistry.
A complete blood cell count was determined twice weekly. Tumor
evaluation according to the WHO response criteria was performed
at baseline and after every two oral courses of therapy.
Sample Collection for Pharmacokinetic Analysis.
Blood samples for pharmacokinetic analysis, collected in 4.5-ml
glass tubes containing lithium heparinate as anticoagulant, were
obtained on the first day after i.v. administration and on the first and
fourth or fifth day of the first oral treatment course for all patients.
Samples were taken at the following time points: before dosing and
at 10, 20, 30, and 45 min then 1.5, 3, 4.5, 6, 8, 10, and 24 h after
the start of the i.v. administration and after the first and either the
fourth or fifth administration of oral diflomotecan. Additional sam-
ples were taken 48 h after the i.v. administration and before oral
administration on days 3 and 4. Immediately after sampling, tubes
were placed on ice and centrifuged at 2000 g for 15 min at 4°C.
For each sample, two aliquots of plasma of 1 ml were placed in
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polypropylene tubes and frozen at	80°C until analysis. Urine was
collected for 24 h on day 1 after i.v. difomotecan and after oral
diflomotecan on days 1 and 5.
Pharmacokinetic Assays. The plasma concentrations of
BN80915 and BN80942 (code name of the corresponding inactive
open lactone form) were determined by LC-MS/MS using 13C-
labeled analogues of BN80915 (BN81011) and BN80942
(BN81012). All structure formulas are presented in Fig. 1. The
lower limit of quantification was 0.05 ng/ml plasma for both
BN80915 and BN80942. For the determination of BN80915 and
BN80942 in human urine, the analytical method involved extract-
ing the analytes with diethyl ether followed by the same LC-
MS/MS method; the limits of quantification were 0.25 and 0.5
ng/ml for BN80915 and BN80942, respectively. The precision of
the analytical technique in plasma for BN80915 was between 7.4
and 10.9% (CV) accuracy was between 2.6 and 0.42% (percentage
of relative error); for BN80942, the precision and accuracy were
8.8–15.0 and 0.05–5.0%, respectively. In urine, the precision and
accuracy of the analytical technique were between 5.3–18.9%
(CV), with relative error (percentage) 2.5 and 5.5% for BN80915.
For BN80942, the CV percentage ranged from 10.4 to 17.4%,
whereas relative error ranged from 10.4 to 3.7%.
Pharmacokinetic Data Analysis. The pharmacokinetic
analyses of BN80915 and BN80942 plasma concentration-time
data set after i.v. and oral administration were performed by a
noncompartmental approach using a WinNonLin pharmacoki-
netic program (version 2.1, Scientific Consulting, Inc., 1998).
The following pharmacokinetic parameters were determined:
empirical time of peak plasma level (Tmax); the empirical peak
plasma level (Cmax); and the apparent elimination rate constant
(
z), estimated by linear regression of the terminal phase of the
semilogarithmic plasma levels curve when this was clearly
defined. The elimination half-life (t1/2) was defined as ln2/
z.
The AUC was estimated by the linear-log trapezoidal rule. The
AUC ratio of BN80915/total was calculated where total 
BN80915BN80942. The absolute oral bioavailability of
BN80915 (F), expressed in percentages, was calculated by
dividing the AUCoral/doseoral ratio by the AUCi.v./dosei.v. ratio of
BN80915.
After i.v. and oral administrations, the amount of un-
changed drug excreted in the urine was determined and ex-
pressed as 9% of the administered dose. Pharmacokinetic data
are reported as mean  SD.
RESULTS
A total of 22 patients entered this study and received the
oral formulation of diflomotecan between June 1999 and De-
cember 2000. Patient characteristics are listed in Table 1. All
patients were eligible and assessable for both toxicity and re-
sponse.
The majority of patients had mild disease-related symp-
toms at baseline. Nine patients were female and 13 male.
Twenty patients had received prior chemotherapy, the median
number of regimens being 2, but 1 patient had previously
received stem cell transplantation after myeloablative chemo-
therapy. This patient was treated at the first dose level and had
no myelotoxicity. Ten patients had received prior radiotherapy.
The most common tumor types were colorectal cancer, adeno-
carcinoma of unknown primary origin, and sarcoma. The flat
oral dose levels of diflomotecan studied were 0.10, 0.20, 0.27,
and 0.35 mg/day. The total number of assessable courses was
57, and the median number of courses/patient was 2 (range,
1–8).
Myelosuppression was the principal DLT. Five patients
required dose reductions after experiencing DLT. Once dose
reduction had taken place, toxicity of subsequent courses ad-
ministered to the patients was incorporated in the evaluation of
that lower dose level.
Fig. 1 Chemical structure of diflomotecan BN80915 (active lactone
form), BN80942 (inactive open ring form), and its analogues BN81011
and BN81012, respectively.
Table 1 Patient characteristics
No. of
patients
Patients entered 22
Patients assessable for toxicity 22
Age, (yr)
Median 55
Range 34–71
Sex
Female 9
Male 13
Performance status
Median 1
Range 0–2
Tumor type
Colorectal 5
Sarcoma 4
Adenocarcinoma of unknown
primary origin
3
Melanomaa 2
Ovarian cancer 2
Otherb 6
Previous therapy
Chemotherapy 20
No. of chemotherapy regimens
Median 2
Range 0–3
Radiotherapy and
chemotherapy
10
a One patient also had renal cell carcinoma.
b Mesothelioma, head and neck, cervical, breast, anal, and prostate
cancer.
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Hematological Toxicity. The severity of hematological
toxicity was clearly dependent on the dose level (Table 2). At
the 0.27-mg oral dose, 1 of the initial 6 patients treated had DLT
in the form of grade 4 neutropenia for 12 days, permitting
escalation to the next dose level. However, at the 0.35-mg dose
level, 2 of 4 patients had DLT. One of these patients had febrile
neutropenia and grade 4 neutropenia for 11 days, the other had
grade 3 thrombocytopenia with recurrent epistaxis requiring
platelet transfusion and associated with grade 4 neutropenia
lasting 13 days. Because 2 of 4 patients had experienced DLT,
no additional dose escalation was attempted. Six additional
patients were included at the dose level immediately below that
which was unacceptably toxic, to further characterize the safety
profile, pharmacokinetic parameters, and pharmacodynamic re-
lationships at the dose recommended for additional studies. Of
these additional 6 patients treated with 0.27 mg of oral diflo-
motecan, 2 experienced DLT consisting of grade 4 neutropenia
for 7 days; 1 of these patients had febrile neutropenia without
other signs of infection. Both patients continued treatment at the
lower dose level of 0.2 mg for one and three cycles, respec-
tively, until disease progression. Hence, a total of 3 of 12
patients experienced DLT at the 0.27-mg dose level, which was
defined as the RD according to the protocol. All 3 patients
experiencing DLT at the RD were heavily pretreated with more
than or equal to two lines of prior chemotherapy. Moreover,
only 2 of 31 courses at the RD were delayed because of
prolonged neutropenia. All DLTs were hematological, and tox-
icity at the RD was easily manageable.
The median time to neutrophil nadir was 8 days (range,
7–13 days). Blood transfusions were given with 17 of 57 cycles
to 45.5% of patients (10 of 22); but only one platelet transfusion
was required.
Nonhematologic Toxicity. Gastrointestinal toxicity was
mild (Table 3) and mainly a result of the unpleasant taste of
diflomotecan. Diarrhea was rare and never clinically serious,
with grade 3 diarrhea observed only once and lasting just a few
hours. Only 2 patients experienced grade 2 mucositis during a
single cycle. Fatigue was frequently observed but often related
to disease progression or anemia. Three patients, who had
baseline grade 1 or 2 fatigue, experienced grade 3 fatigue related
to disease progression. A relationship with the study drug could
not be ruled out in several other cases of grade 1 or 2 fatigue.
Alopecia was seen in 10 of the 22 patients, but in 4, this was
present at baseline. One patient experienced grade 3 vertigo, but
this was not observed on rechallenge with the study medication
and was therefore not considered related. Nephrotoxicity grade
1 was observed in 1 patient but resolved with continued treat-
ment. There was no grade 4 nonhematological toxicity.
Antitumor Activity. No objective responses were ob-
served. However, 6 patients had disease stabilization after two
cycles of diflomotecan. One of these patients with pulmonary
metastases from an anal carcinoma withdrew consent to addi-
tional treatment after two cycles but remained free of disease
progression for 9 months. Another patient with colon carcinoma
completed eight cycles and was still without signs of disease
progression 1 year after start of the treatment. The other 4
patients, with desmoplastic round cell sarcoma, cervical cancer,
cancer of unknown primary and clear cell sarcoma, developed
Table 2 NCI-CTC grade worst hematological toxicity and DLTs of oral diflomotecan (all cycles)
Dose
mg/day
No. of patients/
no. of cycles
Leukocytopenia (Grade) Neutropenia (Grade) Thrombocytopenia (Grade) Anemia (grade)
3 4 3 4 3 4 3a 4
0.10 3/6 0 0 0 0 0 0 0 0
0.20 3/5 1 0 1 0 0 0 1 0
0.20b 3/5 2 0 1 1 1 0 0 0
0.27 12/29 3 3 1 5c 1 0 1 0
0.27b 2/2 1 1 1 1 1 0 1 0
0.35 4/10 2 2 0 2d 2e 0 2 0
a All, except for 1, patients experiencing grade 3 anemia had grade 1 or 2 at baseline.
b Dose level after dose reduction.
c Three DLTs: 3 patients had grade 4 neutropenia  7 days, complicated by fever in 1 patient.
d One DLT: 1 patient had febrile neutropenia (also grade 4 neutropenia  7 days).
e One DLT: 1 patient had grade 3 thrombocytopenia with bleeding, requiring platelet transfusion (with also grade 4 neutropenia  7 days).
Table 3 Worst NCI-CTC grade nonhematological toxicity of oral diflomotecan (all cycles)
Dose
mg/day
No. of patients/
no. of cycles
Nausea (grade) Vomiting (grade) Diarrhea (grade) Fatigue (grade)
2 3 2 3 2 3 2 3
0.10 3/6 0 0 0 0 0 0 1a 0
0.20 6b/10 1 0 0 0 0 1 1 0
0.27 14c/31 5 0 2 0 2 0 8d 0
0.35 4/10 0 0 0 0 1 0 2 0
a Patient had grade 1 at baseline.
b Three patients after dose reduction.
c Two patients after dose reduction.
d Four patients with grade 1 at baseline.
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progressive disease after two to four subsequent cycles of di-
flomotecan.
Pharmacokinetics and Pharmacodynamics. Pharma-
cokinetics could be evaluated in 18 patients, 1 each at the 0.2
and 0.35 mg/day dose levels and 2 at the 0.27 mg/day dose level
being inevaluable. Mean plasma levels (SD) for BN80915
(closed ring) and BN80942 (open ring) at each i.v. and oral dose
level are shown in Figs. 2 and 3, respectively.
The pharmacokinetic parameters of BN80915 and the AUC
ratio for BN80942 after the first and fifth oral administration are
Fig. 2 Mean plasma levels of diflomotecan (BN80915) and its open lactone form (BN80942) after i.v. short infusion of diflomotecan at 0.1, 0.2, and
0.27 mg.
Fig. 3 Mean plasma levels of BN80915 (top) and BN80942 (bottom) after repeated oral administrations of diflomotecan at 0.1, 0.2, 0.27, and
0.35 mg.
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presented in Table 4. The AUC was underestimated at the lowest
dose level as results from the later time points were below the limit
of detection. The mean oral bioavailability (SD) was 72.24 
59.2% across all dose levels. No significant changes in pharmaco-
kinetic parameters were observed between the first and fifth ad-
ministration at the RD level. The AUC and Cmax were proportional
to dose, and the Tmax was independent of dose, indicating a linear
and dose-independent kinetics. Urine analysis revealed that at the
RD level the mean percentage of dose excreted in the urine was
5.44% in the 24 h after first administration and 4.33% in the 24 h
after final dose. The mean ratios of BN80942/BN80915 in urine
after i.v. and p.o. were 2.8 and 2.9, respectively (data not shown).
Renal elimination accounts, therefore, for only a small proportion
of total drug clearance.
Pharmacodynamic relationships between BN80915 AUC
or Cmax and percentage of fall of WBCs, neutrophils, and
platelets, using Emax model, were established at the three highest
dose levels (data not shown).
To test the appropriateness of flat dosing strategy in this
study, the BSA was plotted versus the absolute apparent CL/F
(calculated by dividing the absolute administered oral dose of
diflomotecan by the AUC of BN80915) in Fig. 4. As expected,
no relationship was found between the apparent CL/F and BSA.
DISCUSSION
This study shows that oral administration of diflomotecan
as a solution is feasible in adult patients with solid tumors.
Diflomotecan was well tolerated, with gastrointestinal toxicity
and fatigue limited and few patients experiencing alopecia. Only
1 patient experienced short-lasting grade 3 diarrhea and 4 pa-
tients grade 2 diarrhea This is in marked contrast to irinotecan
where diarrhea is severe (grade 3–4) in 25% of patients (13).
As with other oral topoisomerase I inhibitors, bone marrow
depression was the main toxicity. At the RD level, 3 of 12
patients had neutropenia lasting 7 days and 1 experienced
febrile neutropenia but without other signs of infection or sepsis;
all 3 of these patients were heavily pretreated. Dose delays
because of prolonged hematological toxicity were rare. Many
patients entered the study with grade 1 or 2 anemia, and al-
though no more than a two grade increase in anemia was
observed, erythrocyte transfusion policy was liberal. The per-
centage of patients requiring blood transfusions (45.5%) wasn’t,
therefore, excessive. Indeed this is in the range reported for
other oral topoisomerase I inhibitors in Phase I studies using the
same 5-day schedule (48–55%; Refs. 14, 15).
We conclude that treatment toxicity was acceptable at the
RD level of 0.27 mg once daily  5, every 3 weeks.
Antitumor activity was not a primary end point, and the
patient population was relatively heavily pretreated with few pa-
tients having tumors such as colon cancer that might be expected to
be sensitive to diflomotecan. Nevertheless, one of the patients with
stabilization of their disease for a prolonged period of time on oral
diflomotecan had metastatic colon cancer. Taken with the preclin-
ical data, this suggests that Phase II testing of oral diflomotecan
should include patients with colorectal cancer.
Oral diflomotecan has a linear dose-independent pharmaco-
kinetic profile over the higher part of the dose range studied with
significant inter- and intrapatient variability. Accumulation of
BN80915 was not observed after multiple administrations of diflo-
motecan. The urinary excretion of BN80915 was very low, indi-
cating that elimination is mainly through extrarenal mechanisms.
As for many other chemotherapeutic agents, it was interesting to
note that there was no correlation between BSA and absolute CL/F,
vindicating the flat-dosing regimen used in this study. Population
pharmacokinetic models might identify means of reducing the
Table 4 BN80915 pharmacokinetics and AUC ratio with total (BN80915  BN80942) after first and fifth day oral administration
of diflomotecan
NOTE: Data are expressed as mean  SD, Tmax*, median value.
Dose
(mg/day)
No. of
patients
AUC
(ngh/ml)
Cmax
(ng/ml)
Ratio
BN80915/total Tmax* (h) t1/2 (h) F (%)
0.1
Day 1 3 0.89  0.99 0.50  0.21 0.44(n  1) 0.50 0.94  0.73 16.8(n  1)
Day 5 3 1.62  0.58 1.07  0.86 0.34(n  1) 1.50 1.55  0.35
0.2
Day 1 2 0.96  0.83 0.76  0.24 0.44(n  1) 0.51 1.14  1.17 37.3–18.1(n  2)
Day 5 2 1.36  1.29 0.70  0.25 ND 0.88 1.07  0.74 54.5–21.3(n  2)
0.27
Day 1 10 11.79  7.21 2.64  1.20 0.40  0.10 0.51 3.89  2.06 64.7  36.1(n  10)
Day 5 10 14.47  10.46 3.27  3.13 0.40  0.09 0.75 3.72  1.43 111.7  127.6(n  8)
0.35
Day 1 3 18.03  11.88 4.22  0.77 0.45  0.24 0.75 5.70  2.67 97.1  20.60(n  3)
Day 5 3 11.26  6.15 3.02  1.42 0.45  0.20 0.82 3.29  1.00 63.1  12.8(n  3)
Fig. 4 Relationship between BSA/m2 and absolute CL/F (flat dose
divided by the AUC of BN80915), expressed in liter/h.
4106 Phase I Pharmacological Study of Oral Diflomotecan
inter- and intrapatient variability in the future. Until then, the more
convenient flat dosing of diflomotecan is as accurate as the more
complex dosing by body surface area. Pharmacodynamic relation-
ships of oral diflomotecan AUC and Emax with percentage decrease
in WBCs, neutrophils, and platelets were demonstrated that should
render toxicities predictable. These pharmacodynamic relationships
also raise the prospect of developing pharmacokinetic models to
facilitate individualized dosing, thus avoiding excessive toxicity or
subtherapeutic drug levels.
Compared with other oral topoisomerase I inhibitors that are
administered in similar schedules (14–19), oral diflomotecan has a
range of (pre)clinical advantages. In addition to the superior anti-
tumor activity in vivo, this study indicates that nonhematological
toxicity was less common and less severe than with most other oral
topoisomerase I inhibitors (20), whereas hemorrhagic cystitis was
never encountered. As expected, the E-ring modification leading to
enhanced preclinical stability resulted in a high BN80915/total
ratio, an additional potential advantage in terms of antitumor ac-
tivity. Also of note interest is the exceptionally high oral bioavail-
ability of diflomotecan (72.2%). This compares favorably with
other oral topoisomerase I inhibitors: 11.3% for lurtotecan; 32–
44% for topotecan; and 48.6% for 9-AC (20). One of the reasons
for the high variability in oral bioavailability, also observed in other
oral topoisomerase I inhibitors, might be related to individual
differences in intestinal drug efflux transporters such as Breast
Cancer Resistance Protein.
In conclusion, the recommended flat dose of oral diflomote-
can for Phase II studies in adults, is 0.27 mg once daily 5, every
3 weeks. Oral diflomotecan is well tolerated and has a favorable,
although variable, pharmacokinetic profile with high lactone sta-
bility and acceptable bioavailability. Given the broad and superior
preclinical activity along with enhanced stability, compared with
other topoisomerase I inhibitors and hints of activity in this study,
Phase II studies in a range of solid tumor types are warranted.
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